NVIDIA Blackwell
4 use cases using this technology
Roche scales NVIDIA AI factories globally to accelerate drug discovery, diagnostics and manufacturing
Roche
Roche is deploying more than 3,500 NVIDIA Blackwell GPUs across hybrid cloud and on-premises environments in the U.S. and Europe, expanding an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses. AI is central to Genentech's Lab-in-the-Loop drug discovery strategy, where nearly 90% of eligible small-molecule programs integrate AI; in one program a degrader molecule for oncology was designed 25% faster, and in another AI helped deliver a backup drug candidate in seven months instead of more than two years. Roche is also using NVIDIA Omniverse to build digital twins of manufacturing sites, including its new GLP-1 facility in North Carolina, uses NVIDIA Parabricks software to enable insights across vast datasets, is evaluating the BioNeMo platform for molecular design and chemistry innovation, and uses NVIDIA NeMo Guardrails to ensure safe and reliable healthcare-grade AI.
Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions
Roche
Roche deployed 2,176 NVIDIA Blackwell GPUs on premises across the United States and Europe, bringing its combined on-premise and cloud GPU infrastructure to more than 3,500 Blackwell GPUs. The AI factory is embedded across the value chain: NVIDIA BioNeMo powers Roche's Lab-in-the-Loop strategy connecting biological and chemistry experiments with AI models in R&D; NVIDIA Omniverse-powered digital twins optimize manufacturing production lines and factory designs; accelerated computing and NVIDIA Parabricks analyze diagnostics datasets and digital pathology images; and NVIDIA NeMo Guardrails support healthcare-grade conversational AI in digital health. The expansion builds on a NVIDIA collaboration that started in 2023, and Roche's U.S. subsidiary Genentech also leverages the infrastructure for drug discovery.
MediaTek Accelerates AI Development With an AI Factory
MediaTek
MediaTek established an on-premises AI factory powered by NVIDIA DGX SuperPOD with NVIDIA Blackwell-based systems to accelerate enterprise AI efforts, including development of its Breeze series LLMs and a 480-billion-parameter traditional-Chinese model. The AI factory processes approximately 60 billion tokens per month for inference and completes over 24,000 model-training iterations monthly, training models exceeding 480 billion parameters within one week (versus 7-billion-parameter models in a week previously). Using NVIDIA NIM and TensorRT-LLM, MediaTek achieved a 40% improvement in inference speed and 60% increase in token throughput. NVIDIA Mission Control consolidated GPU provisioning and system monitoring, while AI-assisted code completion and an AI agent for chip design documentation reduced documentation time from weeks to days. NVIDIA Riva was integrated into NVIDIA DGX Spark for agentic voice control features like internet search, calendar and messaging.
Mayo Clinic deploys NVIDIA DGX SuperPOD to accelerate pathology foundation models
Mayo Clinic
Mayo Clinic deployed an NVIDIA DGX SuperPOD with NVIDIA DGX B200 systems to support foundation model development for pathomics, drug discovery and precision medicine. In partnership with Aignostics, Mayo Clinic built the Atlas pathology foundation model, trained on more than 1.2 million histopathology whole-slide images. The new infrastructure is reducing four weeks of pathology slide analysis work to one week.